These are the only FDA and FDA unlabeled uses for growth hormone:
Treatment of growth failure due to inadequate endogenous growth hormone secretion (Genotropin®, Humatrope®, Norditropin®, Nutropin®, Nutropin AQ®, Omnitrope®, Saizen®, Tev-Tropin®)
Treatment of short stature associated with Turner syndrome (Genotropin®, Humatrope®, Norditropin®, Nutropin®, Nutropin AQ®)
Treatment of Prader-Willi syndrome (Genotropin®)
Treatment of growth failure associated with chronic renal insufficiency (CRI) up until the time of renal transplantation (Nutropin®, Nutropin AQ®)
Treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by 2 years of age (Genotropin®) or by 2-4 years of age (Humatrope®, Norditropin®)
Treatment of idiopathic short stature (nongrowth hormone-deficient short stature) defined by height standard deviation score (SDS) ≤ -2.25 and growth rate not likely to attain normal adult height (Genotropin®, Humatrope®, Nutropin®, Nutropin AQ®)
Treatment of short stature or growth failure associated with short stature homeobox gene (SHOX) deficiency (Humatrope®)
Treatment of short stature associated with Noonan syndrome (Norditropin®)
HIV patients with wasting or cachexia with concomitant antiviral therapy (Serostim®)
Replacement of endogenous growth hormone in patients with adult growth hormone deficiency who meet both of the following criteria (Genotropin®, Humatrope®, Norditropin®, Nutropin®, Nutropin AQ®, Omnitrope®, Saizen®):
Biochemical diagnosis of adult growth hormone deficiency by means of a subnormal response to a standard growth hormone stimulation test (peak growth hormone ≤5 mcg/L). Confirmatory testing may not be required in patients with congenital/genetic growth hormone deficiency or multiple pituitary hormone deficiencies due to organic diseases.
Adult-onset: Patients who have adult growth hormone deficiency whether alone or with multiple hormone deficiencies (hypopituitarism) as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma
Childhood-onset: Patients who were growth hormone deficient during childhood, confirmed as an adult before replacement therapy is initiated
Treatment of short-bowel syndrome (Zorbtive®)
USE - UNLABELED / INVESTIGATIONAL - Investigational: Pediatric HIV patients with wasting/cachexia (Serostim®); HIV-associated adipose redistribution syndrome (HARS) (Serostim®)
Anything not included here still needs to be proven with more randomized controlled trials... which is why it's not approved by the FDA.
and btw I'm opting out of this question, maybe some other expert can help affirm your beliefs.